ERAS Key Statistics, Chart & Performance
The current stock price of ERAS is 6.76 USD. In the past month the price increased by 107.36%. In the past year, price increased by 185.84%.
ERAS Latest News, Press Relases and Analysis
ERAS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About ERAS
Company Profile
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Company Info
ERASCA INC
3115 Merryfield Row, Third Floor
San Diego CALIFORNIA US
Employees: 103
Phone: 18584656511
ERASCA INC / ERAS FAQ
Can you describe the business of ERASCA INC?
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
What is the stock price of ERASCA INC today?
The current stock price of ERAS is 6.76 USD. The price increased by 16.35% in the last trading session.
Does ERAS stock pay dividends?
ERAS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ERAS stock?
ERAS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ERASCA INC (ERAS) based on its PE ratio?
ERASCA INC (ERAS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).
Can you provide the market cap for ERASCA INC?
ERASCA INC (ERAS) has a market capitalization of 1.92B USD. This makes ERAS a Small Cap stock.
Can you provide the short interest for ERAS stock?
The outstanding short interest for ERASCA INC (ERAS) is 7.44% of its float.
ERAS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ERAS. When comparing the yearly performance of all stocks, ERAS is one of the better performing stocks in the market, outperforming 98.92% of all stocks.
ERAS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERAS. While ERAS has a great health rating, there are worries on its profitability.
ERAS Financial Highlights
Over the last trailing twelve months ERAS reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 45.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.37% | ||
| ROE | -36.7% | ||
| Debt/Equity | 0 |
ERAS Forecast & Estimates
15 analysts have analysed ERAS and the average price target is 4.99 USD. This implies a price decrease of -26.23% is expected in the next year compared to the current price of 6.76.